Short-term efficacy and safety of palliative radiotherapy combined with apatinib in treating advanced lung cancer

HE Zhongxiang; WANG Chengshi; PU Juan; YU Hanxu; LIU Yanyan; ZHU Lijing; SUN Xinchen

doi:10.7619/jcmp.20211258

Journal of Clinical Medicine in Practice > 2021 > 25(13): 68-71. > DOI: 10.7619/jcmp.20211258

HE Zhongxiang, WANG Chengshi, PU Juan, YU Hanxu, LIU Yanyan, ZHU Lijing, SUN Xinchen. Short-term efficacy and safety of palliative radiotherapy combined with apatinib in treating advanced lung cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(13): 68-71. DOI: 10.7619/jcmp.20211258

Citation:

PDF (535 KB)

Short-term efficacy and safety of palliative radiotherapy combined with apatinib in treating advanced lung cancer

1.
Lianshui People's Hospital Affiliated to Kangda College of Nanjing Medical University, People's Hospital of Lianshui County of Jiangsu Province, Huaian, Jiangsu, 223400
2.
First Affiliated Hospital of Nanjing Medical University, People's Hospital of Jiangsu Province, Nanjing, Jiangsu, 210018

More Information

Received Date: March 23, 2021
Available Online: July 07, 2021
Published Date: July 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To observe the short-term efficacy and safety of palliative radiotherapy combined with apatinib for advanced lung cancer.
Methods Data of 40 patients with advanced lung cancer was retrospectively studied. Patients were divided into observation group (n=20) and control group (n=20) according to the treatment methods. In the observation group, patients received both palliative radiotherapy and apatinib, while in the control group, patients received palliative radiotherapy only. The total clinical short-term efficacy, clinical symptomscores and incidence of side effects between the two groups were compared.
Results The short-term objective remission rate and disease control rate of the observation group were 70.00% and 90.00%, respectively, which were higher than those of the control group (30.00% and 60.00%, respectively) (P < 0.05). The pain score, asthma score and pleural fluid score in the observation group were significantly lower than those in the control group (P < 0.05). The incidence of hypertension in the observation group was higher than that in the control group (P < 0.05). There was no significant difference in the incidence of other toxic reactions between the two groups (P>0.05).
Conclusion When compared with palliative radiotherapy alone, palliative radiotherapy combined with apatinib shows better short-term effect, improved clinical symptoms and higher safety.
- advanced lung cancer,
- palliative radiotherapy,
- apatinib,
- chemotherapy,
- short-term efficacy,
- safety

FullText(HTML)

References (25)

References

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2]	HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454. doi: 10.1038/nature25183
[3]	KHAN F, SISODIA S. Targeted therapies for treatment of lung cancer-recent advances[J]. Pharm & Biosci J, 2020, 8(3): 22-31. http://www.researchgate.net/publication/342235880_Targeted_Therapies_For_Treatment_of_Lung_Cancer_-_Recent_Advances
[4]	WALDER D, O'BRIEN M. Looking back and to the future: Are we improving "cure" in non-small cell lung cancer[J]. Eur J Cancer, 2017, 75: 192-194. doi: 10.1016/j.ejca.2017.01.006
[5]	LI J, QIN S K, XU J M, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13): 1448-1454. doi: 10.1200/JCO.2015.63.5995
[6]	XU J, LIU X, YANG S, et al. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer[J]. Asia Pac J Clin Oncol, 2018, 14(3): 264-269. doi: 10.1111/ajco.12834
[7]	HU X C, CAO J, HU W W, et al. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14: 820. doi: 10.1186/1471-2407-14-820
[8]	LIU J, XIE S, DUAN X, et al. Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2020, 85(1): 69-76. doi: 10.1007/s00280-019-04004-z
[9]	王鹏善, 孙运祥, 刘玲. 阿帕替尼治疗晚期非小细胞肺癌的近期疗效及不良反应[J]. 现代肿瘤医学, 2018, 26(9): 1365-1367. doi: 10.3969/j.issn.1672-4992.2018.09.013
[10]	SATEIA H, CHOI Y, STEWART R, et al. Screening for lung cancer[J]. Semin Oncol, 2017, 44(1): 74-82. doi: 10.1053/j.seminoncol.2017.02.003
[11]	KUON J, VOGT J, MEHNERT A, et al. Symptoms and needs of patients with advanced lung cancer: early prevalence assessment[J]. Oncol Res Treat, 2019, 42(12): 650-659. doi: 10.1159/000502751
[12]	PHILLIPS I, KESTENBAUM S. Optimising patient fitness: strategies to reduce the effects of cancer Cachexia in patients with advanced lung cancer[J]. Curr Opin Support Palliat Care, 2020, 14(4): 304-308. doi: 10.1097/SPC.0000000000000525
[13]	NORMAN M B, JAMES D C. Radiotherapy for lung cancer[J]. Int J Radiat Oncol, 1985, 11(5): 1001-1007. doi: 10.1016/0360-3016(85)90123-3
[14]	MATSUO Y. A systematic literature review on salvage radiotherapy for local or regional recurrence after previous stereotactic body radiotherapy for lung cancer[J]. Technol Cancer Res Treat, 2018, 17: 1533033818798633. http://www.researchgate.net/publication/327557267_A_Systematic_Literature_Review_on_Salvage_Radiotherapy_for_Local_or_Regional_Recurrence_After_Previous_Stereotactic_Body_Radiotherapy_for_Lung_Cancer
[15]	PARKER S M, SIOCHI R A, WEN S, et al. Impact of tumor size on local control and pneumonitis after stereotactic body radiation therapy for lung tumors[J]. Pract Radiat Oncol, 2019, 9(1): e90-e97. doi: 10.1016/j.prro.2018.09.003
[16]	NI Y, YE X. Angiogenesis and apatinib: Can be used for the patients with non-gastic cancer[J]. J Cancer Res Ther, 2018, 14(4): 727-729. doi: 10.4103/jcrt.JCRT_222_18
[17]	XU Z, WANG I Z, KUMARASWAMY L K, et al. Evaluation of dosimetric effect caused by slowing with multi-leaf collimator (MLC) leaves for volumetric modulated arc therapy (VMAT)[J]. Radiol Oncol, 2016, 50(1): 121-128. doi: 10.1515/raon-2016-0008
[18]	MANNING G, TICHY A, SIRÁK I, et al. Radiotherapy-associated long-term modification of expression of the inflammatory biomarker genes ARG1, BCL2L1, and MYC[J]. Front Immunol, 2017, 8: 412. http://pubmedcentralcanada.ca/pmcc/articles/PMC5385838/
[19]	VEERAVAGU A, HSU A R, CAI W B, et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy[J]. Recent Pat Anti Cancer Drug Discov, 2007, 2(1): 59-71. doi: 10.2174/157489207779561426
[20]	FALCON B L, CHINTHARLAPALLI S, UHLIK M T, et al. Antagonist antibodies to vascular endothelial growth factor receptor 2(VEGFR-2) as anti-angiogenic agents[J]. Pharmacol Ther, 2016, 164: 204-225. http://europepmc.org/abstract/med/27288725
[21]	WU S, ZHOU J J, GUO J, et al. Apatinib inhibits tumor growth and angiogenesis in PNET models[J]. Endocr Connect, 2019, 8(1): 8-19. doi: 10.1530/EC-18-0397
[22]	KAN X, LIANG B, ZHOU G, et al. Transarterial chemoembolization combined with apatinib for advanced hepatocellular carcinoma: a propensity score matching analysis[J]. Front Oncol, 2020, 10: 970. doi: 10.3389/fonc.2020.00970
[23]	DING J, CHENG X Y, LIU S, et al. Apatinib exerts anti-tumour effects on ovarian cancer cells[J]. Gynecol Oncol, 2019, 153(1): 165-174. doi: 10.1016/j.ygyno.2019.01.010
[24]	赵瑞华, 周亚楠, 李鹤, 等. 阿帕替尼对晚期非小细胞肺癌患者的疗效及VEGFR2-906T>C多态性位点的影响[J]. 中华医学杂志, 2019, 99(2): 105-110. doi: 10.3760/cma.j.issn.0376-2491.2019.02.006
[25]	吴莹莹, 周江云. 阿帕替尼联合调强放疗治疗中晚期非小细胞肺癌的疗效分析[J]. 中国医师杂志, 2020, 22(2): 289-292. doi: 10.3760/cma.j.issn.1008-1372.2020.02.033

[1]	GAO Xianru, ZENG Qingping, LI Mengyao, LI Yuping, TAN Yuerong, WANG Jia, SHI Tian. Bibliometric analysis of domestic and foreign studies on dysphagia after stroke in the past decade[J]. Journal of Clinical Medicine in Practice, 2023, 27(3): 127-133. DOI: 10.7619/jcmp.20223226
[2]	YANG Ling, LEI Ming, CHEN Qun, ZHAO Xiao, YU Xiaoxia. Clinical study on Weijin Xiangjiao acupuncture in the treatment of dysphagia after ischemic stroke[J]. Journal of Clinical Medicine in Practice, 2022, 26(20): 30-34. DOI: 10.7619/jcmp.20221050
[3]	BAI Xue, LI Bing, LI Hua, GONG Qiwei, FENG Ling. Effect of early swallowing and feeding intervention on dysphagia and quality of life in postoperative patients with tongue cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(12): 46-50. DOI: 10.7619/jcmp.20220199
[4]	DAI Suyun, XIANG Wenhai, CUI Lisheng, OUYANG Yuchen, DING Jie, FENG Huiping, DONG Jiahao. Oral sensation training in patients with dysphagia and salivation after stroke[J]. Journal of Clinical Medicine in Practice, 2022, 26(2): 6-10. DOI: 10.7619/jcmp.20213872
[5]	XU Jiehui, HAO Zhina, PIAO Jingjing, GU Yanmei. Effect of timing acupoint stimulation for dysphagia patients after stroke[J]. Journal of Clinical Medicine in Practice, 2021, 25(17): 70-75. DOI: 10.7619/jcmp.20211546
[6]	HU Yue. Rehabilitation nursing of traditional Chinese medicine in patients with dysphagia after stroke[J]. Journal of Clinical Medicine in Practice, 2020, 24(11): 78-81. DOI: 10.7619/jcmp.202011022
[7]	CHEN Xinxing, TIAN Ling. Timing selection of acupuncture and rehabilitation training for patients with dysphagia after stroke[J]. Journal of Clinical Medicine in Practice, 2020, 24(6): 123-125. DOI: 10.7619/jcmp.202006034
[8]	LIU Guoju, DING Yun, CHENG Yuefeng, LIANG Caihong. Effect of drinking water test combined with swallowing training for the treatment of cerebral infarction patients with dysphagia[J]. Journal of Clinical Medicine in Practice, 2018, (2): 5-8. DOI: 10.7619/jcmp.201802002
[9]	ZHAO Feili, ZHANG Chunni. Effect of time rehabilitation nursing on functional rehabilitation of cerebral infarction patients with dysphagia[J]. Journal of Clinical Medicine in Practice, 2016, (6): 10-12. DOI: 10.7619/jcmp.201606004
[10]	Ayshemgul·Shadr, ZHAO Jie, YANG Yunxin. Effect observation of different approaches in the treatment of dysphagia in patients with cerebral stroke[J]. Journal of Clinical Medicine in Practice, 2014, (18): 72-74. DOI: 10.7619/jcmp.201418023

Cited By

Cited by

Periodical cited type(1)

万姜维，成东茹，王涛，高萍. 血清乳酸脱氢酶、β_2微球蛋白、铁蛋白联合改良WHO预后积分系统预测骨髓增生异常综合征预后不良的价值. 实用临床医药杂志. 2024(05): 79-84 .

本站查看

Other cited types(0)

Get Citation

PDF

XML

Article views (505) PDF downloads (27) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Short-term efficacy and safety of palliative radiotherapy combined with apatinib in treating advanced lung cancer

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Short-term efficacy and safety of palliative radiotherapy combined with apatinib in treating advanced lung cancer

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Export File

Citation

Format

Content